SCHEMBL14306286

SCHEMBL14306286

CC(=O)NCc1ccc(C(F)(F)F)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.51
NAMPT P43490 2/20 0.50
SYK P43405 2/20 0.46
KCNQ3 O43525 1/20 0.46
KCNQ2 O43526 1/20 0.46
KCNQ4 P56696 1/20 0.46
KCNQ5 Q9NR82 1/20 0.46
KMT2A Q03164 1/20 0.46
GLS O94925 1/20 0.46
KDM1A O60341 1/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
KCNH2 Q12809 1/20 0.45
CSF1R P07333 1/20 0.44
ENPP2 Q13822 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
GRIA2 P42262 1/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30791579 1.00 TRPV1 (0.51) TRPV1NAMPTSYKKCNQ3KCNQ2
SCHEMBL20249197 0.86 KMT2A (0.47) KMT2AHDAC1HDAC6ALDH1A1KDM4E
SCHEMBL22501639 0.86 TRPV1 (0.52) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL4853173 0.85 TRPV1 (0.49) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL19318505 0.85 PTGES (0.55) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL31236179 0.84 TRPV1 (0.51) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL14279029 0.84 PTGES (0.56) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL30074796 0.82 TRPV1 (0.52) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL28907319 0.82 TRPV1 (0.52) TRPV1NAMPTKCNQ3KCNQ2KCNQ4
SCHEMBL10263975 0.81 L3MBTL1 (0.50) TRPV1NAMPTKCNQ3KCNQ2KCNQ4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170253614-A1 HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) 2017-09-07 US disclosed
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253614-A1 HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS HAVCR2, HCCS, LIPC TRPV1 3957/4885NAMPT 331/4885SYK 2471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.